Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer

15 Feb 2008

Abstract excerpt

PURPOSE: Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT. PATIENTS AND METHODS: A cohort of 529 men with advanced prostate cancer treated with ADT was genotyped for 129 DNA polymorphisms distributed across 20 genes involved in androgen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research
Share to Sexual Differentiation and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18281655
DOI: 10.1200/jco.2007.13.6804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate CancerPMID 18281655Read ↗

Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.Semantic proximity Read ↗

Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.Semantic proximity Read ↗

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.Semantic proximity Read ↗

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.Semantic proximity Read ↗

Germline predictors of androgen deprivation therapy response in advanced prostate cancer.Semantic proximity Read ↗

Inherited variation in hormone-regulating genes and prostate cancer survival.Semantic proximity Read ↗

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.Semantic proximity Read ↗

Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.Semantic proximity Read ↗

Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.Semantic proximity Read ↗

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.Semantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.